NSE/TORNTPHARM (NSE/TORNTPHARM)

National Stock Exchange of India: NSE/TORNTPHARM · INR

₹4,557

-67.99 (-1.5%)· Recorded snapshot

Market cap	1.7T
Revenue (ttm)	174B
Net income (ttm)	21.2B
EPS (ttm)	₹59.1
P/E (trailing)	77.1x
P/E (forward)	59.7x
Dividend	₹38.0 (0.83%)
Volume	238,803
Beta	0.14

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 174B
Net income (ttm): 21.2B
EPS (ttm): ₹59.1
P/E (trailing): 77.1x
P/E (forward): 59.7x
Market cap: 1.7T

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E59.7

P25 n/aP50 n/aP75 n/a

Trailing P/E77.1

P25 n/aP50 n/aP75 n/a

ROE15.7

P25 n/aP50 n/aP75 n/a

ROIC9.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NSE/TORNTPHARM indicators

Market & fundamental data

Available fields

250

Groups with data

Currency

INR

Showing 250 of 250 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	INR
Country	India
Country code	IN
Earnings date	2026-10-23
Employees	18,258
Employees change	1,199
Employees growth	7.03%
Enterprise value	INR 1.8T
Exchange	National Stock Exchange of India
Financial currency	INR
Financial report date	2026-09-30
First seen	2026-05-10
Fiscal year end	March
Founded	1959
Industry	Drug Manufacturers - Specialty & Generic
Is primary listing	No
ISIN number	INE685A01028
Last earnings date	2026-10-23
Last refreshed	2026-10-28
Last stock split date	2022-07-08
Last stock split type	Forward
Market cap	INR 1.7T
Next earnings date	2027-01-27
Price	INR 4,557.00
Price currency	INR
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	nse/TORNTPHARM
Website	https://www.torrentpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	74.23x
Average P/E ratio (10Y)	48.92x
Average P/E ratio (3Y)	61.46x
Average P/E ratio (5Y)	58.74x
Earnings yield	1.3%
EV/Earnings	86.89x
EV/EBIT	47.85x
EV/EBITDA	32.05x
EV/FCF	51.76x
EV/Sales	10.61x
FCF / EV yield	1.93%
FCF yield	2.06%
Forward P/E	59.71x
Graham number	778.52654
Graham upside	-82.92%
Industry forward P/E	33.08x
Industry P/E	38.9x
Lynch fair value	INR 607.86
Lynch upside	-86.66%
P/B ratio	9.44x
P/E ratio	77.08x
P/FCF ratio	48.64x
P/OCF ratio	39.1x
P/S ratio	9.97x
Price/EBITDA ratio	30.37x
Sector forward P/E	36.12x
Sector P/E	45.5x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	22.17%
EBITDA margin	32.83%
Effective tax rate	25.38%
FCF margin	20.5%
Gross margin	75.85%
Operating margin	22.17%
Pretax margin	16.17%
Profit margin	12.21%
Profit per employee	INR 1.2M
Profitable quarters	18
Profitable years	22
Revenue per employee	INR 9.5M
ROA	8.02%
ROA (5Y)	9.55%
ROCE	10.53%
ROE	15.65%
ROE (5Y)	20.5%
ROIC	9.64%
ROIC (5Y)	15.33%
Tax / revenue	4.1%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-6.51%
EPS growth (Q)	-19.48%
EPS growth (QoQ)	-5.51%
EPS growth 10Y	6.52%
EPS growth 3Y	14.2%
EPS growth 5Y	9.58%
EPS growth years	4
FCF growth	162.57%
FCF growth 3Y	13.78%
FCF growth 5Y	18.89%
Gross profit growth	42.38%
Gross profit growth (Q)	50.08%
Gross profit growth 3Y	20.79%
Gross profit growth 5Y	17.23%
Net income growth	-0.74%
Net income growth (Q)	-9.65%
Net income growth (QoQ)	-5.65%
Net income growth 3Y	16.51%
Net income growth 5Y	10.89%
Net income growth years	4
OCF growth	128.68%
OCF growth 3Y	15.64%
OCF growth 5Y	20%
Operating income growth	21.01%
Operating income growth (Q)	20.25%
Operating income growth 3Y	18.97%
Operating income growth 5Y	15.68%
Revenue growth	42.06%
Revenue growth (Q)	50.79%
Revenue growth (QoQ)	1.18%
Revenue growth 10Y	11.21%
Revenue growth 3Y	19.36%
Revenue growth 5Y	16.23%
Revenue growth quarters	27
Revenue growth years	9

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	INR -8.7B
Depreciation and amortization	INR 18.5B
EBIT	INR 38.6B
EBITDA	INR 57.1B
EPS	INR 59.12
Financing cash flow	INR 94.7B
Free cash flow	INR 35.7B
Gross profit	INR 132B
Income taxes	INR 7.1B
Investing cash flow	INR -136.8B
Net borrowing	INR 113B
Net cash flow	INR 2.7B
Net income	INR 21.2B
Operating income	INR 38.6B
Revenue	INR 174B

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	INR 483.41
Debt / EBITDA	2.45
Debt / equity	0.77
Debt / FCF	3.96
Goodwill	INR 39.9B
Interest coverage	4.36
Long-term assets	INR 341B
Long-term liabilities	INR 182.6B
Net cash (debt)	INR -111.2B
Net cash / market cap	-6.41%
Net debt / EBITDA	1.95
Net debt / equity	0.61
Net debt / FCF	3.12
Piotroski F-Score	5
Property, plant and equipment	INR 54.7B
Shareholders' equity	INR 183.7B
Tangible book value	INR -91.7B
Tangible book value per share	INR -241.24
Total assets	INR 446.2B
Total cash	INR 29.9B
Total debt	INR 141.1B
Total liabilities	INR 262.4B
WACC	4.97%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.58
Current assets	INR 105.2B
Current liabilities	INR 79.8B
Current ratio	1.32
Inventory turnover	1.49
Net working capital	INR 18.5B
Quick ratio	0.8
Working capital	INR 25.3B
Working capital turnover	8.11

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-6.17%
Dividend growth	18.75%
Dividend growth (10Y)	8.06%
Dividend growth (3Y)	19.98%
Dividend growth (5Y)	16.77%
Dividend growth years	2
Dividend payment years	24
Dividend payout frequency	Semi-Annual
Dividend per share	INR 38.00
Dividend yield	0.83%
Ex-dividend date	2026-05-29
Last dividend	INR 9.00
Payout ratio	69.05%
Shareholder yield	-5.33%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	539.24%
10Y return CAGR	21.84%
10Y total return	620.61%
150-day SMA	INR 4,623.89
15Y price change	3,059.36%
15Y return CAGR	27.72%
15Y total return	3,827.8%
1D price change	-1.47%
1M price change	-8.65%
1M total return	-8.65%
1W price change	-0.04%
1W total return	-0.04%
1Y price change	26.71%
1Y return CAGR	27.85%
1Y total return	27.83%
20-day SMA	INR 4,651.38
200-day SMA	INR 4,504.92
20Y price change	9,092.13%
20Y return CAGR	27.25%
20Y total return	12,285.99%
3M price change	-9.21%
3M total return	-9.21%
3Y price change	137.26%
3Y return CAGR	34.66%
3Y total return	144.22%
50-day SMA	INR 4,822.59
50-day SMA vs 200-day SMA	50over200
52-week high	INR 5,250.00
52-week high date	2026-08-03
52-week low	INR 3,532.60
52-week low date	2025-11-06
5Y price change	223.03%
5Y return CAGR	27.96%
5Y total return	242.97%
6M price change	7.99%
6M total return	8.21%
All-time high	INR 5,250.00
All-time high date	2026-08-03
All-time low	INR 9.69
All-time low date	2003-04-28
Average true range (ATR)	INR 113.10
Average volume	325.7K
Beta (5Y)	0.14
Change from 52-week high	-13.2%
Change from 52-week low	29%
Change from all-time high	-13.2%
Change from all-time low	46,937.57%
Change from open	-0.87%
Day's gap	-0.6%
Dollar volume	INR 1.1B
High price	INR 4,597.10
Low price	INR 4,486.60
Monthly RSI	64.24
Open price	INR 4,597.10
Position in 52-week range	63.71%
Previous close	INR 4,625.00
Price vs 150-day SMA	-1.45%
Price vs 20-day SMA	-2.03%
Price vs 200-day SMA	1.16%
Price vs 50-day SMA	-5.51%
Relative volume	0.73
RSI	39.5
Sharpe ratio	1.06
Sharpe ratio (3Y)	1.31
Sharpe ratio (5Y)	0.91
Sortino ratio	1.99
Sortino ratio (3Y)	2.36
Sortino ratio (5Y)	1.62
Volume	238.8K
Weekly RSI	48.06
YTD price change	18.36%
YTD total return	19.41%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	146.8M
Shares change (QoQ)	-0.15%
Shares change (YoY)	6.17%
Shares held by insiders	0%
Shares held by institutions	19.75%

Deeper analysis on NSE/TORNTPHARM

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NSE/TORNTPHARM report

Is a complete NSE/TORNTPHARM research report available?

No complete published report is available for nse/TORNTPHARM (NSE/TORNTPHARM) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

NSE/TORNTPHARM (NSE/TORNTPHARM)

Price

Financial snapshot

Fair-value bridge

Latest news · NSE/TORNTPHARM

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NSE/TORNTPHARM indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NSE/TORNTPHARM

Frequently asked questions